MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Official Title

An open-label, multicenter, non-randomized phase 2 study of elranatamab monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody


The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Trial Description

Primary Outcome:

  • objective response rate
Secondary Outcome:
  • duration of response
  • cumulative complete response rate
  • duration of cumulative complete response
  • progression free survival
  • time to response
  • minimal residual disease negativity rate
  • frequency of treatment-emergent adverse events
  • frequency of laboratory abnormalities
  • concentrations of elranatamab (PF-06863135)
  • immunogenicity of elranatamab (PF-06863135)
  • overall survival

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society